Lixte Biotechnology to Present at DealFlow Discovery Conference as LB-100 Clinical Development Advances

Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) announced its participation in the DealFlow Discovery Conference scheduled for January 28–29, 2026, in Atlantic City, New Jersey. Chief Executive Officer Geordan Pursglove will conduct one-on-one meetings with investors during the conference as the company continues advancing LB-100, its first-in-class inhibitor of protein phosphatase 2A, through clinical development. This participation matters because it represents a critical opportunity for the clinical-stage pharmaceutical company to engage with the investment community while progressing a novel cancer treatment approach that could significantly improve patient outcomes.

The company's lead compound, LB-100, represents a pioneering effort in an entirely new field of cancer biology called activation lethality, which is advancing a new treatment paradigm. Lixte has demonstrated that LB-100 is well-tolerated in cancer patients at doses associated with anti-cancer activity, based on extensive published preclinical data available at https://www.lixte.com. The compound has the potential to significantly enhance both chemotherapies and immunotherapies, offering new hope for patients with difficult-to-treat cancers. This development is important because current cancer treatments often face limitations in efficacy and tolerability, making novel approaches like LB-100 particularly valuable in oncology research.

Proof-of-concept clinical trials are currently in progress for ovarian clear cell carcinoma and metastatic colon cancer, two challenging cancer types where improved treatment options are urgently needed. The company's comprehensive patent portfolio protects this new approach, providing intellectual property security as development continues. The latest news and updates relating to LIXT are available in the company's newsroom at http://ibn.fm/LIXT, offering investors and stakeholders ongoing access to development progress.

InvestorWire, the specialized communications platform distributing this announcement, provides advanced wire-grade press release syndication as part of the Dynamic Brand Portfolio at IBN. The platform delivers access to a vast network of wire solutions, article and editorial syndication to over 5,000 outlets, enhanced press release features, social media distribution to millions of followers, and tailored corporate communications solutions. More information about InvestorWire is available at https://www.InvestorWire.com, with full terms of use and disclaimers accessible at https://www.InvestorWire.com/Disclaimer.

The conference participation comes at a significant time for Lixte Biotechnology as the company moves LB-100 through clinical development. The implications of this announcement extend beyond mere investor relations, highlighting the ongoing advancement of a potentially transformative cancer therapy that operates through a novel biological mechanism. As cancer remains a leading cause of death worldwide, with limited treatment options for many advanced cancers, the progress of LB-100 through clinical trials represents an important development in oncology research that could eventually benefit patients facing difficult treatment scenarios.